Background: O6-Methyl-Guanine-Methyl-Transferase (MGMT) silencing by promoter
Introduction
Alkylating agents such as dacarbazine and temozolomide (TMZ) are currently used in the clinical management of lymphomas, melanomas and as first-line treatment for glioblastoma (GBM) in addition to surgical resection and radiotherapy. Action of these drugs is enhanced in tumors with inactive O6-Methyl-Guanine-Methyl-Transferase (MGMT), which is the DNA repair enzyme in charge of removing DNA alkylated adducts [1] . Defective MGMT function mainly results from its transcriptional silencing by gene promoter methylation. Therefore, MGMT methylation has been proposed as a predictive marker of response to alkylating agents [2] [3] [4] [5] . Nevertheless, not all patients with MGMT hypermethylated tumors respond to treatment with alkylating agents [6, 7] .
MGMT silencing has also been found to occur in several other malignancies [8, 9] , including colorectal cancer (CRC) [8, 9] . The reported high prevalence of this marker in CRC (30-40%) has led to several trials which have recently evaluated the clinical activity of alkylating agents in the metastatic setting [10] [11] [12] [13] . Collectively, these studies showed that clinical benefit could be achieved in up to 40% of heavily pre-treated patients [11] [12] [13] .
Despite minor differences in response rates and progression-free survival (PFS), all the above studies reported that only a fraction of MGMT methylated cases derived clinical benefit from treatment with dacarbazine or TMZ. We hypothesize that the relatively poor specificity of MGMT status as a predictive marker of response to alkylating agents could be explained by an inaccurate assessment of methylation due to sampling issues, tumor heterogeneity or suboptimal detection methods.
Here we implemented the detection of MGMT methylation through the methyl beads, emulsion, amplification, and magnetics protocol also known as Methyl-BEAMing assay [14] . We validated the predictive prognostic value of MGMT methylation testing in two GBM cohorts. We tested whether this technique could improve the assessment of MGMT methylation and the selection of CRC patients with higher probability of response to alkylating agents. We then compared it to commonly used methods, including Methylation Specific PCR [MSP] [15] and Bisulfite Pyrosequencing [Bs-Pyrosequencing] [16] . Finally, we evaluated the ability of the Methyl-BEAMing assay to detect tumor methylation status directly from plasma samples of CRC patients to evaluate the feasibility of patient selection for treatment via a blood test.
Material and Methods

Patients and sample preparation
A first GBM training-set included tissue samples from 98 patients who had undergone brain surgery at the Academic Medical Center in Amsterdam, between 1988 and 2006 [17] .
A second GBM validation-set consisted of 66 tissue samples from patients with newlydiagnosed GBM, who had surgery and chemoradiation (radiotherapy and concomitant TMZ, followed by six monthly cycles of adjuvant TMZ) with a follow-up of at least two years at the VU University Medical Center in Amsterdam. The DETECT-01 trial composed the CRC training-set, in which 68 patients with chemorefractory metastatic CRC (mCRC) were treated with dacarbazine [11] . The validation-set consisted of 23 samples from a phase II trial, in which 32 patients with chemorefractory metastatic CRC (mCRC) were treated with TMZ [13] . Further details about the cohorts and the sample preparation can be found in Data S1. The studies followed the Declaration of Helsinki and were approved by local ethics committees.
MGMT methylation assays
MGMT methylation was retrospectively assessed in tissue sample DNA using MSP, Bspyrosequencing and Methyl-BEAMing. Analyses were performed in a blinded fashion without prior knowledge of MGMT methylation status. Cell-free circulating DNA (cfDNA) (cfDNA) was assessed by Methyl-BEAMing. All the assays targeted CpGs within the differentially methylated region number 2 previously associated with TMZ response [18] .
Detailed protocols are provided in Data S1. Sensitivity, reproducibility and specificity of MGMT Methyl-BEAMing assays can be found in Data S2.
Quality control of cfDNA
Three different assays were used to evaluate the presence of cfDNA from tumor origin (circulating tumor DNA, ctDNA): Methyl-BEAMing assays specific for SEPT9 and VIM methylation (markers highly prevalent in mCRC) and Droplet Digital™ PCR assays for the KRAS mutational status for samples known to be mutated in the tumor tissue (Data S1).
Statistical Analyses
Survival analyses and kappa statistics were performed using Prism 6.01 for Windows (GraphPad Software). Differences in survival were tested by the log-rank test (Mantel-Cox).
ROC analyses were performed with R bioconductor using the pROC package [19] .
Hazard-Ratios were expressed using the log-rank test. All expressed p-values were calculated with two-tailed tests and were considered significant when p<0.05.
Results
Prognostic and predictive value of MGMT methylation in GBM
MGMT methylation is a well-known prognostic marker in GBM [8] . In order to establish the prognostic value of MGMT status assessed by Methyl-BEAMing, we employed tissue samples from a cohort of 98 patients with GBM diagnosed before TMZ was introduced as component of standard treatment for these tumors [17] . Table S1 and Data 
S3E-G. OS and PFS according to methylation status by both techniques are shown in
Prognostic and predictive value of MGMT methylation in mCRC
The DETECT-01 study evaluated dacarbazine treatment for mCRC patients after failure of standard therapies. The original report determined MGMT methylation status via MSP and found that 44% of patients in the methylated subgroup achieved disease control as assessed by radiological methods, although no improvement in PFS was observed [11] . Table S1 . ROC analysis was performed to define the best threshold in cfDNA (Data S4C). Thirty-eight unmethylated cases (75.6%) were identified. To verify the presence of DNA from tumor origin (circulating tumor DNA, ctDNA), we assessed KRAS mutational status for the 20 cases with known G12 or G13 mutation in the corresponding tumor tissue, as well as SEPT9 and VIM methylation in all samples.
Methylated SEPT9 and VIM are two early markers of detection of intestinal disease reported with over 85% prevalence in mCRC [14, 20] . Six samples were considered as low ctDNA (four KRAS mutated and two wild type cases) since they displayed neither KRAS mutation nor methylation in SEPT9 or VIM in plasma ( Figure 1D ) despite showing these alterations in the corresponding tissue (data not shown).
Out of the 49 available plasma samples only 43 had remaining matched tissue that could be assessed for tumor content and MGMT methylation. Concordance was seen in 37 cases (86.1%) (six methylated and 31 unmethylated cases; Figure 1E ; Data S4I).
Correlation between the MGMT methylation status in tissue and plasma samples indicates that most of the methylated alleles present in the tissue were released in the blood (Spearman correlation= 0.53, p=0.0003).
MGMT methylated status in cfDNA was also associated with a significantly improved median PFS (2.1 months vs. 1.8 months for unmethylated group, p=0.008, Table S1 , Data S4E). Among the available plasma samples, seven were obtained from patients with clinical benefit from dacarbazine treatment. MGMT methylated status was observed in 11 (22%) plasma and identified five of the seven patients achieving clinical benefit ( Figure 1F , Data S4F). Among the two unmethylated cases with clinical benefit, one did not have remaining tissue sample DNA and the second was considered as low ctDNA.
Discussion
MGMT methylation has been previously identified as a prognostic and predictive marker in GBM [2] [3] [4] [5] . However its specificity for response prediction in GBM and other cancer types remains controversial. MGMT methylation status is usually evaluated by MSP or BsPyrosequencing [15, 16] . Notably, recent phase II clinical trials in mCRC with alkylating agent therapies relied on MSP evaluation of MGMT [11] [12] [13] for patient selection or evaluation of response prediction. These studies demonstrated that up to 40% of heavily pretreated mCRC patients achieved some clinical benefit, indicating that drug repositioning could be helpful in this setting upon improved patient selection [21] . Here, we describe the use of Methyl-BEAMing, a highly sensitive and reproducible technique for the detection of MGMT methylation in tissue and plasma samples derived from cancer patients.
Prognostic significance of MGMT methylated status assessed by Methyl-BEAMing in GBM was improved compared to MSP or Bs-Pyrosequencing. Predictive value of MGMT methylated status for response to TMZ was also observed with a better stratification using Methyl-BEAMing compared to Bs-Pyrosequencing. Plasma samples were not available for the GBM patients, thereby preventing us from assessing the potential role of liquid biopsy in this setting. While the blood brain barrier may limit the amount of cfDNA in patients affected by CNS malignancies [22] , it has been shown that real-time PCR can be used to detect MGMT methylation in the plasma of glioblastoma patients receiving TMZ [23] .
Further studies are therefore warranted to clarify the role of liquid biopsy in GBM [24] .
Our study retrospectively assessed two mCRC cohorts for which DNA was extracted from Of interest, a number of GBM cases showed intra-locus heterogeneity by BsPyrosequencing (also described by Bady et al. using a methylation microarray platform [18] ); while this pattern was rarely seen in the mCRC samples (Data S4I). As the current Bs-Pyrosequencing is the average of the six evaluated CpG sites, its accuracy might suffer from the heterogenous profiles observed in GBM as well as by incomplete bisulfite conversion. Therefore we hypothesize that this could explain the discrepancy of performance between Bs-Pyrosequencing and Methyl-BEAMing in the two tissue types.
It is also possible that MGMT methylation heterogeneity exists among individual tumor cells and that MGMT immunostaining could be used in combination with methylation based methods to better refine selection of patients [25] . However, so far, observer variability and lack of association with patient survival has hampered the use of immunohistochemistry as clinical biomarker in GBM [26, 27] . Studies that have addressed the role of MGMT immunostaining as predictive biomarker of response in CRC are limited to case reports [10] and further investigations are needed in larger cohorts.
Plasma samples were only available for patients in the mCRC training cohort. We successfully assessed all cases via Methyl-BEAMing demonstrating high efficiency even with samples of poor quality and limited quantity. Reliability of the results was limited in a few instances by the observation that cfDNA samples are not only composed of DNA of tumor origin [22] . Therefore we evaluated SEPT9 and VIM methylation, and KRAS mutation (when the tissue demonstrated an alteration) in cfDNA. Six samples out of 49
showed the absence of all these markers, strongly suggesting the absence of ctDNA. Use of higher volume of plasma or exploitation of micro-vesicles, such as exosomes [28] could potentially solve this issue. Discrepancies between the plasma and tissue could be mainly explained by the low abundance of ctDNA. In the remaining cases, we hypothesized that the tumor might have evolved between the time of diagnosis (tissue collection) and the treatment (plasma collection) since this period could have been longer than 10 years. An ongoing study including fresh biopsies is being performed to investigate whether and to what extent there is change of MGMT methylated status over time [29] . Nevertheless, the present comparison of plasma and tissue samples showed that cfDNA could be used as a good surrogate to tissue biopsies when the tumor load is controlled and normalized. To achieve this aim, optimization of house-keeping genes highly methylated in cancer and poorly methylated in blood is required. Development of such markers for each cancer type might be required and would enable a better use of alkylating agents across several malignancies.
In conclusion, regardless of the DNA origin (FFPE tissue or plasma) assessment of MGMT 
